Abstracts tagged "rituximab and treatment options"

Abstract Number: 387 • 2016 ACR/ARHP Annual Meeting
Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Sunil Sampath^1,2, Liza J. McCann³, Michael W. Beresford^3,4, Eileen Baildam³, Jamie C Sergeant^1,5, Wendy Thomson², Helen Foster⁶, Sharon Douglas², Taunton Southwood⁷, Kimme L. Hyrich¹ and Biologics for Children with Rheumatic Diseases (BCRD) study Group¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁷School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Selective peripheral B-cell depletion by rituximab (RTX) is a relatively recent advance in rheumatic diseases. RTX is an approved treatment in RA. Although very…
Abstract Number: 954 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Different Dosages of Retreatment of Rituximab in Combination with Leflunomide: Results from a Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study
Frank Behrens¹, Tanja Rossmanith², Michaela Koehm³, Rieke Alten⁴, Martin Aringer⁵, GR Burmester⁶, Eugen Feist⁷, Klaus Krüger⁸, Ulf Müller-Ladner⁹, Andrea Rubbert-Roth¹⁰, Siegfried Wassenberg¹¹, Hans-Peter Tony¹², Herbert Kellner¹³, Marina Backhaus¹⁴ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ⁴Schlosspark-Klinik University Medicine, Berlin, Germany, ⁵Abteilung für Rheumatologie, Dresden, Germany, ⁶Charité – University Medicine Berlin, Berlin, Germany, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Praxiszentrum St. Bonifatius, München, Germany, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰Division Rheuamatology, University Köln, Köln, Germany, ¹¹Rheumazentrum, Ratingen, Germany, ¹²Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹³Rheumatology Patient Care, Munchen, Germany, ¹⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany
Background/Purpose: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases…
Abstract Number: 3199 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry
julien henry¹, stéphane pavy², Jacques Gottenberg³, rakiba belkhir⁴, Stéphanie Rouanet⁵, Jérémie Sellam⁶, Xavier Mariette⁷ and raphaèle seror⁴, ¹departement of rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ²rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ³Hautepierre, Strasbourg, France, ⁴Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁵Biostatistics, Roche France, Boulogne-Billancourt, France, ⁶Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ⁷Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: In RA patients, different randomized clinical trials have showed that the efficacy of reduced dose of RTX either initially and for subsequent courses (DANCER,…
Abstract Number: 504 • 2014 ACR/ARHP Annual Meeting
Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries
Axel Finckh¹, David Neto², M. Victoria Hernández³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhao⁶, K Pavelka⁷, Carl Turesson⁸, Xavier Mariette⁹, Merete Lund Hetland¹⁰ and Jacques Gottenberg¹¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²University of Geneva, Geneva, Switzerland, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ⁷Institute of Rheumatology, Prague, Czech Republic, ⁸Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁰DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose Some observations have suggested that the effectiveness of abatacept (ABA) may be decreased in rheumatoid arthritis (RA) patients (pts) who previously failed rituximab (RTX).(1)…
Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴, Dan Nemes⁵, Rodica Chirieac⁶, Paulina Ciurea⁷, Maria Suta⁸, Andra Balanescu⁹, Eugenia Mociran¹⁰ and Elena Rezus¹¹, ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁶C.M.I. Rodica Chirieac, Iasi, Romania, ⁷Emergency County Hospital, Craiova, Romania, ⁸Emergency County Hospital, Constanta, Romania, ⁹Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ¹⁰Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].